

The Canadian Journal of Neurological Sciences

Le Journal Canadien des Sciences Neurologiques

SPECIAL FEATURES

- **The Cerebral Ischemic Penumbra**
Antoine Hakim 557
- **Commentary on the Significance for Modern Neurology of the 17th Century B.C. Surgical Papyrus**
Cathy M. Helgason 560

ORIGINAL ARTICLES

- **Amyloid Angiopathy in Alzheimer's Disease**
C. Bergeron, P.J. Ranalli and P.N. Miceli 564
- **Metabolic Changes in Cerebral Gliomas Within Hours of Treatment With Intra-Arterial BCNU Demonstrated by Phosphorus Magnetic Resonance Spectroscopy**
Douglas L. Arnold, Eric A. Shoubridge, William Feindel and others 570
- **A Comparison of Bromocriptine (Parlodel®) and Levodopa-Carbidopa (Sinemet®) For Treatment of "De Novo" Parkinson's Disease Patients**
Israel Libman, Marek J. Gawel, Richard J. Riopelle and others 576
- **Neuropathie Périphérique Cryoglobulinémie Mixte Syndrome Sec**
J-Ph. Thenint, M.J. Penniello, F. Chapon and others 581
- **Epidemiology of Primary Intracranial Neoplasms in Manitoba, Canada**
G.R. Sutherland, R. Florell, D. Louw and others 586
- **Asymmetric Papilledema and Visual Loss in Pseudotumour Cerebri**
Charles E. Maxner, Mark I. Freedman and James J. Corbett 593
- **Attentional and Perseverative Impairment in Two Cases of Familial Fatal Parkinsonism with Cortical Sparing**
D. Kimura, A. Hahn and H.J.M. Barnett 597
- **Contrast Enhancing Lesions in Progressive Multifocal Leukoencephalopathy: A Clinicopathological Correlation**
Bronislava Shafran, Marian E. Roke, Robert M. Barr and others 600
- **Prolonged Progressive Multifocal Leukoencephalopathy Without Immunosuppression**
Douglas W. Zochodne and John C.E. Kaufmann 603
- **Focal Pontine Leukoencephalopathy in a Patient with the Shwachman-Diamond Syndrome**
Vei Mah, Lee Nelson and Harry V. Vinters 608
- **Symposium Summary**
Amyotrophic Lateral Sclerosis: Concepts in Pathogenesis and Etiology 649
- **Guidelines for the Diagnosis of Brain Death** 653

(complete Table of Contents page iii)



XXIIIrd Canadian Congress of
Neurological Sciences

June 14-18, 1988

Call for Abstracts — page 662

The Official Journal of

The Canadian Neurological Society
The Canadian Neurosurgical Society
The Canadian Society of Clinical Neurophysiologists
The Canadian Association for Child Neurology

Volume 14, No. 4

November 1987

HEADACHE:
Prescribe
the products
that set
the standards

FIORINAL[®]

(ASA/caffeine/butalbital)

For tension headache and migraine

Complete headache therapy
from SANDOZ

FIORINAL[®] -C^{1/4}

FIORINAL[®] -C^{1/2}

(ASA/caffeine/butalbital/codeine)

For more severe migraine
and tension headaches



CAFERGOT[®]
(ergotamine tartrate/caffeine)

Therapy to abort acute
vascular headache



SANDOMIGRAN DS[®]
(pizotyline hydrogen malate)

Prophylaxis for
chronic recurring
vascular headache


SANDOZ[®]



SANDOZ CANADA INC.,
Whitby, Ontario, L1N 5Z5
Mailing Address: Dorval, Qc, H9R 4P5

Precaution: Fiorinal-C^{1/4}, C^{1/2} have the potential for being abused and should be avoided in chronic pain states leading to continuous daily use.

Full prescribing information available to
physicians and pharmacists on request. 



The logical way to look into the brain is through our window.

It all depends on how you look at it, of course. But when we set out to develop a superior neurodiagnostic system, we thought isn't it more logical to ask clinicians first what their needs were? That's when our engineers got to work and designed the QSI 9000. For you. We invite you to look at the result of 7 years of development and clinical testing.

The QSI 9000 is the ultimate electrophysiologic diagnostic system in one versatile unit. With unparalleled computer power. And full 20 channel EEG and Evoked Potential capability.

QSI 9000 has been designed to look out for the future too, with maximum adaptability to advances in computer technology.

Now you can provide comprehensive EEG exams, Evoked Potential studies and the latest in Topographical Mapping without the high cost of acquiring and operating multiple diagnostic units. The QSI 9000 puts it all together. With a result that we think might surprise you. It costs less.

One look, you'll see QSI 9000's color images are faster, easier to interpret. And the system is IBM compatible so you can take advantage of the wide range of existing statistical programs.

Putting it all together, the QSI 9000 makes sense. That's why we call it the Electrophysio-Logical answer to today's neurodiagnostic needs. For more information call (416) 449-7050



QSI 9000

The Electrophysio-Logical System.

Quantified Signal Imaging Inc.
26 Lesmill Road, North York, Ontario M3B 2T5 (416) 449-7050



Editor/Rédacteur en chef Robert G. Lee *Calgary*
Associate Editors/Rédacteurs associés Yves Lamarre *Montreal* Harvey B. Sarnat *Calgary*
Founding Editor/Fondateur-rédacteur Robert T. Ross *Winnipeg*
Book Review Editor/Rédacteur de critiques de livres T. Peter Seland *Calgary*
Managing Editor/Adjoint administratif Sally A. Gregg *Calgary*

Editorial Board/Conseil Scientifique

Albert J. Aguayo <i>Montreal</i>	André Olivier <i>Montreal</i>
Henry J.M. Barnett <i>London</i>	Donald Paty <i>Vancouver</i>
Larry Becker <i>Toronto</i>	Sidney J. Peerless <i>London</i>
Paul Bédard <i>Quebec</i>	Terry Picton <i>Ottawa</i>
George Ebers <i>London</i>	Jean Reiher <i>Sherbrooke</i>
Guy Geoffroy <i>Montreal</i>	Leo P. Renaud <i>Montreal</i>
William J. Logan <i>Toronto</i>	Matthew W. Spence <i>Halifax</i>
Morton Low <i>Vancouver</i>	John Stewart <i>Montreal</i>
John Murphy <i>Toronto</i>	Charles Tator <i>Toronto</i>
Thomas J. Murray <i>Halifax</i>	Simon Verret <i>Quebec</i>

Bryce Weir *Edmonton*

Publications Committee/Comité de Rédaction

John Wherrett <i>Toronto</i>	Warren Blume <i>London</i>
Terry Myles <i>Calgary</i>	John Tibbles <i>Halifax</i>

The Official Journal of:/La Revue Officielle de:

The Canadian Neurological Society

La Société Canadienne de Neurologie

President/Président — T. Peter Seland
Secretary-Treasurer/ — William McCormick,
Secrétaire-Trésorier Box 2148, Dickson Centre,
Victoria General Hospital,
Halifax, Nova Scotia
B3H 2Y9

The Canadian Society of Clinical Neurophysiologists

La Société Canadienne de Neurophysiologues Clinics

President/Président — R. Gordon Blair
Secretary-Treasurer/ — Werner J. Becker,
Secrétaire-Trésorier 841 Centre Avenue East,
Calgary, Alberta
T2E 0A1

The Canadian Neurosurgical Society

La Société Canadienne de Neurochirurgie

President/Président — Francis E. LeBlanc
Secretary-Treasurer/ — Alain Godon,
Secrétaire-Trésorier 12361 Notre-Dame-des Anges St.,
Montreal, Quebec
H4J 2C3

The Canadian Association for Child Neurology

L'Association Canadienne de Neurologie Pédiatrique

President/Président — Robert H.A. Haslam
Secretary-Treasurer/ — Daniel Keene,
Secrétaire-Trésorier Suite 208, 150 Montreal Road,
Vanier, Ontario
K1L 8H2

The Canadian Journal of Neurological Sciences is published quarterly by University of Calgary Press. The annual subscription rate is \$40.00 for Canada and the U.S.A. \$44.00 elsewhere. Interns, Residents Pre- and Post-Doctoral Students \$20.00 per annum. Single copies \$12.00 each. All communications and subscriptions should be sent to the Editor, Canadian Journal of Neurological Sciences, Room 1496, Faculty of Medicine, University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, Canada T2N 4N1. Telephone: (403) 220-3062. COPYRIGHT © 1987 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Mailed under second class registration number 3307. Postage paid at Calgary, Alberta. This journal is indexed by *Index Medicus*, *Excerpta Medica* and *Current Contents — Clinical Practice and Life Sciences*.

Le Journal Canadien des Sciences Neurologiques est publié trimestriellement par les Presses de l'Université de Calgary. L'abonnement annuel est de \$40.00 pour le Canada et les États-Unis; \$44.00 ailleurs. Internes, résidents, fellows pré et post-doctoral: \$20.00 par an. Toutes les communications et les abonnements doivent être adressés à l'Éditeur, Journal des Sciences Neurologiques, chambre 1496, Faculté de Médecine, Université de Calgary, 3330 Hospital Drive N.W., Calgary, Alberta, T2N 4N1. Téléphone (403) 220-3062. DROITS D'AUTEUR © 1987: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la permission préalable du Journal Canadien des Sciences Neurologiques. Posté sous permis de second classe no 3307. Port payé à Calgary, Alberta. Le journal est cité et indexé dans *Index Medicus*, *Excerpta Medica* et *Current Contents — Clinical Practice et Life Sciences*.

Advertising representative/Représentant de publicité Keith Health Care Communications,
4953 Dundas St. W., Toronto, Ontario, Canada M9A 1B6 — (416) 239-1233

Printer/Imprimeur McAra Printing Limited, 105, 2507 - 12th Street N.E., Calgary, Alberta T2E 7L5

ISSN 0317 - 1671



Table of Contents

SPECIAL FEATURES

The Cerebral Ischemic Penumbra
Antoine Hakim 557

Commentary on the Significance for Modern Neurology of the 17th Century B.C. Surgical Papyrus
Cathy M. Helgason 560

ORIGINAL ARTICLES

Amyloid Angiopathy in Alzheimer's Disease
C. Bergeron, P.J. Ranalli and P.N. Miceli 564

Metabolic Changes in Cerebral Gliomas Within Hours of Treatment With Intra-Arterial BCNU Demonstrated by Phosphorus
Magnetic Resonance Spectroscopy
Douglas L. Arnold, Eric A. Shoubridge, William Feindel and Jean-Guy Villemure 570

A Comparison of Bromocriptine (Parlodel®) and Levodopa-Carbidopa (Sinemet®) For Treatment of "De Novo" Parkinson's
Disease Patients
Israel Libman, Marek J. Gawel, Richard J. Riopelle and Sylvie Bouchard 576

Neuropathie Périphérique Cryoglobulinémie Mixte Syndrome Sec
J-Ph. Thenint, M.J. Penniolo, F. Chapon, A. Beaudoin et P. Morin 581

Epidemiology of Primary Intracranial Neoplasms in Manitoba, Canada
G.R. Sutherland, R. Florell, D. Louw, N.W. Choi and A.A.F. Sima 586

Asymmetric Papilledema and Visual Loss in Pseudotumour Cerebri
Charles E. Maxner, Mark I. Freedman and James J. Corbett 593

Attentional and Perseverative Impairment in Two Cases of Familial Fatal Parkinsonism with Cortical Sparing
D. Kimura, A. Hahn and H.J.M. Barnett 597

Contrast Enhancing Lesions in Progressive Multifocal Leukoencephalopathy: A Clinicopathological Correlation
Bronislava Shafran, Marian E. Roke, Robert M. Barr and J. Gregory Cairncross 600

Prolonged Progressive Multifocal Leukoencephalopathy Without Immunosuppression
Douglas W. Zochodne and John C.E. Kaufmann 603

Focal Pontine Leukoencephalopathy in a Patient with the Shwachman-Diamond Syndrome
Vei Mah, Lee Nelson and Harry V. Vinters 608

Variants of Guillain-Barré Syndrome: Miller Fisher Syndrome, Facial Diplegia and Multiple Cranial Nerve Palsies
Ashfaq Shuaib and Werner J. Becker 611

Longitudinal Multimodal Evoked Potential Studies in Abetalipoproteinaemia
E.R. Fagan and M.J. Taylor 617

Hypoparathyroidism and Pseudotumor Cerebri: An Infrequent Clinical Association
Robert S. Sheldon, Werner J. Becker, David A. Hanley and Ronald L. Culver 622

Kinesigenic Choreoathetosis due to Brain Injury
J.C. Richardson, J.L. Howes, M.J. Celinski and R.G. Allman 626

Response of Tardive and L-Dopa-Induced Dyskinesias to Antidepressants
M. El-Awar, M. Freedman, P. Seeman, L. Goldenberg, J. Little and P. Solomon 629

Pathology of Eosinophilic Fasciitis and its Relation to Polymyositis
Ke-Wei Huang and Xiao-Han Chen 632

Graves' Disease and Subarachnoid Hemorrhage: A Possible Familial Association
Richard Leblanc and Andrés M. Lozano 638

Sensory Discrimination and its Relationship to the Cerebral Processing of Infrequent Stimuli
Douglas S. Goodin, Michael J. Aminoff and Mary M. Mantle 642

Symposium Summary

Amyotrophic Lateral Sclerosis: Concepts in Pathogenesis and Etiology 649

Guidelines for the Diagnosis of Brain Death 653

BOOK REVIEWS 657

NOTES AND ANNOUNCEMENTS 660

CALENDAR OF EVENTS 661

CANADIAN CONGRESS OF NEUROLOGICAL SCIENCES — Call for Abstracts 662


INDEX TO VOLUME 14 663

ADVERTISERS INDEX xiii



***To the parkinsonian patient,
the little things in life make all the difference***



Add
PARLODEL[®] 
(bromocriptine mesylate)
***Because quality
of life is the issue***

SANDOZ


MEMBER
PMAA
PAAB

ACTIONS Parlodel (bromocriptine mesylate) is a dopaminomimetic ergot derivative with D₂ type dopamine receptor agonist activity, and has also D₁ dopamine receptor antagonist properties. The dopaminomimetic activity of bromocriptine in the striatum is considered responsible for the clinical benefits seen in selected patients with Parkinson's disease, when low doses of the drug are gradually added to levodopa therapy in patients on long-term treatment who develop late side effects of levodopa or no longer respond to the medication. Excessive dopaminomimetic drive may, however, provoke psychotic and other adverse reactions.

The extreme variability in G.I. tract absorption and the extensive and individually variable first-pass metabolism are responsible for the broad variability in plasma concentrations of bromocriptine and, in part, for the variability in dose response.

INDICATIONS* Parkinson's Disease: Parlodel (bromocriptine mesylate) has been found to be clinically useful as an adjunct to levodopa (usually with a decarboxylase inhibitor), in the symptomatic management of selected patients with Parkinson's disease who experience prominent dyskinesia or wearing off reactions on long-term levodopa therapy.

Patients on long-term treatment who are beginning to deteriorate on levodopa therapy may be controlled by reducing the dose of levodopa and adjusting the frequency and schedule of drug administration. Patients maintained on optimal dosages of levodopa who still experience prominent dyskinesia and/or end-of-dose failure may benefit from the concomitant use of Parlodel, by decreasing the occurrence and/or severity of these manifestations. Since rapid escalation of bromocriptine doses causes severe adverse reactions, it is recommended to combine a slow increase of Parlodel, usually with a concomitant, gradual and limited reduction of levodopa dosage. Continued efficacy of bromocriptine for more than two years has not been established and there is some evidence that its efficacy tends to wane. Evidence available indicates that there is no consistent benefit from bromocriptine in patients who have not responded previously to levodopa, and studies have shown significantly more adverse reactions in bromocriptine-treated patients than in patients treated with levodopa. Parlodel is not recommended in the treatment of newly diagnosed patients or as the sole medication in Parkinson's disease.

CONTRAINDICATIONS Other than sensitivity to ergot alkaloids, no absolute contraindications to treatment with Parlodel (bromocriptine mesylate) are known. For procedure during pregnancy see "Use in Pregnancy" under Precautions.

WARNINGS Long-term treatment (6-36 months) with Parlodel in doses of 20 to 100 mg/day has been associated with pulmonary infiltrates, pleural effusion and thickening of the pleura in a few patients. Where Parlodel was discontinued, these changes slowly reverted to normal.

PRECAUTIONS Parlodel (bromocriptine mesylate) may cause hypotension, primarily postural; periodic monitoring of the blood pressure, particularly during the first days of therapy, is advisable. In some patients dizziness (vertigo) may occur with Parlodel; patients should therefore be cautioned against activities requiring rapid and precise responses, such as driving an automobile or operating dangerous machinery, until their response has been determined.

Care should be exercised when administering Parlodel concomitantly with phenothiazines or antihypertensive agents. Due to drug interaction at the receptor site, dosage should be adjusted accordingly.

Alcohol should be avoided during treatment with Parlodel. In some patients, the concomitant use of Parlodel and alcohol has given rise to alcohol intolerance and an increase in the severity and incidence of Parlodel's possible adverse reactions.

Parlodel should always be taken with food. In cases

where severe adverse effects, such as nausea, vomiting, vertigo or headaches are severe or persisting, the therapeutic dosage of Parlodel should be reduced to half of one tablet daily (1.25 mg) and increased gradually to that recommended. The dopamine antagonist domperidone may be useful in the control of severe gastrointestinal side effects in parkinsonian patients receiving Parlodel (see Drug Interactions).

As with all medication, Parlodel should be kept safely out of the reach of children.

Use in Pregnancy: If the patient wishes to become pregnant, Parlodel (bromocriptine mesylate) should be stopped as soon as possible after conception is suspected. In this event immunological confirmation should be done immediately. When pregnancy is confirmed, Parlodel, like all other drugs, should be discontinued unless, in the opinion of the treating physician, the possible benefit to the patient outweighs the potential risk to the fetus.

In human studies with Parlodel (reviewed by Turkali, I.), there were 1410 reported pregnancies, which yielded 1236 live and 5 stillborn infants from women who took Parlodel (bromocriptine mesylate) during early pregnancy. Among the 1241 infants, 43 cases (31 minor and 12 major) of congenital anomalies were reported. The incidence (3.46%) and type of congenital malformations and the incidence of spontaneous abortions (11.13%) in this group of pregnancies does not exceed that generally reported for such occurrences in the population at large.

Use in Parkinson's Disease: Use of Parlodel (bromocriptine mesylate), particularly in high doses, may be associated with mental confusion and mental disturbances. Since patients with Parkinson's disease may manifest varying degrees of dementia, caution should be exercised when treating such patients with Parlodel.

Parlodel administered alone or concomitantly with levodopa may cause visual or auditory hallucinations. These usually resolve with dosage reduction, but discontinuation of Parlodel may be required in some cases. Rarely, after high doses, hallucinations have persisted for several weeks following discontinuation of Parlodel. Caution should be exercised when administering Parlodel to patients with a history of myocardial infarction, particularly if they have a residual atrial, nodal or ventricular arrhythmia.

Symptomatic hypotension can occur and, therefore, caution should be exercised when administering Parlodel, particularly in patients receiving antihypertensive medication. Periodic evaluation of hepatic, hematopoietic, cardiovascular and renal function is recommended.

Drug Interactions: The concomitant use of erythromycin may increase bromocriptine plasma levels.

Domperidone, a dopamine antagonist, may cause increases in serum prolactin. In so doing, domperidone may antagonise the therapeutically relevant prolactin lowering effect of Parlodel. It is possible that the antitumorigenic effect of Parlodel in patients with prolactinomas may be partially blocked by domperidone administration.

ADVERSE REACTIONS The most frequently observed adverse reactions are nausea, vomiting, headache and gastrointestinal side effects such as abdominal pain, diarrhea and constipation. All these effects may be minimized or even prevented by giving small initial doses of bromocriptine and by taking it with food.

Postural hypotension which can, on rare occasions, lead to fainting and "shock-like" syndromes has been reported in sensitive patients. This is most likely to occur during the first few days of Parlodel treatment.

When bromocriptine is added to levodopa therapy, the incidence of adverse reactions may increase. The most common newly appearing adverse reactions in combination therapy were: nausea, abnormal involuntary movements,

hallucinations, confusion, "on-off" phenomenon, dizziness, drowsiness, faintness, fainting, vomiting, asthenia, abdominal discomfort, visual disturbance, ataxia, insomnia, depression, hypotension, shortness of breath, constipation and vertigo.

Less common adverse reactions include anorexia, anxiety, blepharospasm, dry mouth, dysphagia, edema of the feet and ankles, erythromelalgia, epileptiform seizures, fatigue, headache, lethargia, mottling of skin, nasal stuffiness, nervousness, nightmares, paresthesia, skin rash, urinary frequency, urinary incontinence, urinary retention and rarely signs or symptoms of ergotism such as tingling of fingers, cold feet, numbness, muscle cramps of feet and legs or exacerbation of Raynaud's syndrome.

Abnormalities in laboratory tests may include elevation of blood urea nitrogen, SGOT, SGPT, GGPT, CPK, alkaline phosphatase and uric acid, which are usually transient and not of clinical significance.

The occurrence of adverse reactions may be lessened by temporarily reducing dosage to one-half tablet two or three times daily.

SYMPTOMS AND TREATMENT OF OVERDOSE There have been several reports of acute overdosage with Parlodel (bromocriptine mesylate) in children and adults. No life threatening reactions have occurred. Symptoms reported included nausea, vomiting, dizziness, drowsiness, hypotension, sweating and hallucinations. Management is largely symptomatic; the cardiovascular system should be monitored. Metoclopramide can be used to antagonize the emesis and hallucinations in patients who have taken high doses.

DOSAGE AND ADMINISTRATION Parlodel (bromocriptine mesylate) should always be taken with food.

Although Parlodel (bromocriptine mesylate) has been found clinically useful in decreasing the severity and frequency of "on-off" fluctuations of late levodopa therapy, the decision to use bromocriptine as adjunctive treatment and the selection of dosage must be individualized in each case. A low dose is recommended. The initial dose of Parlodel is one half of a 2.5 mg tablet (1.25 mg) at bedtime with food to establish initial tolerance. Thereafter, the recommended dosage is 2.5 mg daily in two divided doses, with meals, (half a 2.5 mg tablet twice daily). The dosage may be increased very gradually, if necessary, by adding an additional 2.5 mg per day, once every 2 to 4 weeks, to be taken always in divided doses with meals. Increments should usually not exceed 2.5 mg. Clinical assessments are recommended at two week intervals or less during dosage titration, to ensure that the lowest effective dosage is not exceeded. The usual dosage range is from a few milligrams to 40 mg daily in two or three divided doses with meals. The median dose varies with the experience of individual investigators, but can be around 10 mg daily or higher. During initial titration it is recommended that the dosage of levodopa should be maintained, if possible. Subsequently, it might be desirable to combine a slow increase of bromocriptine with a concomitant, limited and gradual reduction of levodopa.

AVAILABILITY

TABLETS each containing 2.5 mg bromocriptine, as mesylate, available in bottles of 100.

CAPSULES each containing 5 mg bromocriptine, as mesylate, available in bottles of 100.

*For information on other approved indications, please consult the Parlodel product monograph, available to physicians and pharmacists on request.

SANDOZ

Sandoz Canada Inc.
P.O. Box 385
Dorval, Quebec H9R 4P5

Intermediate Prescribing Information

Tegretol® 200 mg
(carbamazepine) tablets

Tegretol® Chewtabs™
(carbamazepine chewable tablets)
100 mg and 200 mg

For Symptomatic Relief of Trigeminal Neuralgia Anticonvulsant

Action:

TEGRETOL (carbamazepine) has anticonvulsant properties which have been found useful in the treatment of psychomotor and other partial epilepsies, when administered in conjunction with other anticonvulsant drugs to prevent the possible generalization of the epileptic discharge. A mild psychotropic effect has been observed in some patients, which seems related to the effect of the carbamazepine in psychomotor or temporal lobe epilepsy. TEGRETOL relieves or diminishes the pain associated with trigeminal neuralgia often within 24 to 48 hours.

Indications and Clinical Use

A. Trigeminal Neuralgia:

For the symptomatic relief of pain of trigeminal neuralgia only during periods of exacerbation of true or primary trigeminal neuralgia (tic douloureux). Do not use preventively during periods of remission. In some patients, TEGRETOL has relieved glossopharyngeal neuralgia.

For patients who fail to respond to TEGRETOL, or who are sensitive to the drug, recourse to other accepted measures must be considered. TEGRETOL is not a simple analgesic and should not be used to relieve trivial facial pains or headaches.

B. TEGRETOL has been found useful:

- 1) in the management of psychomotor (temporal lobe) epilepsy, and,
- 2) as an adjunct, in some patients with secondary or partial epilepsy with complex symptomatology or secondarily generalized seizures, when administered in combination with other antiepileptic medication.
- 3) as an alternative medication in patients with generalized tonic-clonic seizures who are experiencing marked side effects or fail to respond to other anticonvulsant drugs.

TEGRETOL is ineffective in controlling petit mal, minor motor, myoclonic and predominantly unilateral seizures, and does not prevent the generalization of epileptic discharge.

Warnings

Although reported infrequently, serious adverse effects have been observed during the use of TEGRETOL.

Agranulocytosis and aplastic anemia have occurred in a few instances with a fatal outcome. Leucopenia, thrombocytopenia and hepatocellular and cholestatic jaundice have also been reported. It is, therefore, important that TEGRETOL should be used carefully and close clinical and frequent laboratory supervision should be maintained throughout treatment in order to detect as early as possible signs and symptoms of a possible blood dyscrasia. Long-term toxicity studies in rats indicated a potential carcinogenic risk. Therefore, the possible risk of drug use must be weighed against the potential benefits before prescribing carbamazepine to individual patients.

Contraindications

Hepatic disease, serious blood disorder, less than 14 days either before or after monoamine oxidase inhibitor (then the dosage of TEGRETOL should be low initially, and increased very gradually), atrioventricular heart block, hypersensitivity to tricyclic compounds, lactation, first trimester of pregnancy.

Usage in Pregnancy

As safety has not been established, TEGRETOL should not be given to women of childbearing potential unless, in the opinion of the physician, the expected benefits to the patient outweigh the possible risk to the fetus.

Precautions

Monitoring of Haematological and Other Adverse Reactions:

Complete blood studies, including platelet counts, and evaluation of hepatic and renal function and urinalysis should be carried out before treatment is instituted and frequent clinical and laboratory supervision should be maintained throughout treatment. If any signs or symptoms or abnormal laboratory findings suggestive of blood dyscrasia or liver disorder occur, TEGRETOL should be immediately discontinued.

Urinary Retention and Increased Intraocular Pressure:

Caution is advised in patients with increased intraocular pressure or urinary retention due to the drug's anticholinergic action.

Occurrence of Behavioural Disorders:

TEGRETOL may activate a latent psychosis, or, in elderly patients, produce agitation or confusion. Caution is advised in alcoholics.

Use in Patients with Cardiovascular Disorders:

Caution is advised in patients with a history of coronary artery disease, organic heart disease, or congestive failure. An E.K.G. should be performed if a defective conductive system is suspected before administering TEGRETOL, in order to exclude patients with atrioventricular block.

Use in Patients taking Oral Contraceptives:

Women under treatment with TEGRETOL and oral contraceptives, should be advised to use some alternative, non-hormonal method of contraception as the reliability of oral contraceptives may be adversely affected.

Driving and Operating Hazardous Machinery:

Warn patients about the possible hazards of operating machinery or driving automobiles as dizziness and drowsiness are possible side effects of TEGRETOL.

Adverse Reactions

Haematological reactions: Transitory leucopenia, eosinophilia, leucocytosis, thrombocytopenic purpura, agranulocytosis, macrocytic anemia and aplastic anemia. In a few instances, deaths have occurred.

Hepatic Disturbances: Abnormalities in liver function tests, cholestatic or hepatocellular jaundice.

Dermatological Reactions: Skin sensitivity reactions and rashes, erythematous rashes, pruritic eruptions, urticaria, photosensitivity, pigmentary changes, neurodermatitis and in rare cases Stevens-Johnson syndrome, exfoliative dermatitis, alopecia, diaphoresis, erythema multiforme, erythema nodosum, and aggravation of disseminated lupus erythematosus.

Neurological Reactions: Vertigo, dizziness, somnolence, disturbances of coordination, confusion, headache, fatigue, blurred vision, transient diplopia and oculomotor disturbances, speech disturbances, abnormal involuntary movements, increase in motor seizures, peripheral neuritis, paresthesia, depression with agitation, talkativeness, nystagmus, tinnitus, paralysis and other symptoms of cerebral arterial insufficiency.

Cardiovascular Systems: Recurrence of thrombophlebitis, congestive heart failure, aggravation of hypertension, Stokes-Adams in patients with AV block, hypotension, syncope and collapse, edema, aggravation of coronary artery disease. Some of these complications (including myocardial infarction and arrhythmia) have been associated with other tricyclic compounds.

Genitourinary Reactions: Urinary frequency, acute urinary retention, oliguria with elevated blood pressure, impotence, elevation of BUN, albuminuria, and glycosuria.

Digestive Tract: Nausea, vomiting, gastric or abdominal discomfort, diarrhoea, anorexia, dryness of the mouth and throat, glossitis and stomatitis.

Eyes: There is no conclusive evidence that TEGRETOL produces pathological changes in the cornea, lens or retina. However, it should be recognized that many phenothiazines and related drugs have been shown to cause eye changes. By analogy, periodic eye examinations, including slitlamp fundoscopy and tonometry, are recommended.

Other Reactions: Fever and chills, lymphadenopathy, aching joints and muscles, leg cramps and conjunctivitis.

Symptoms and Treatment of Overdosage

Symptoms: Dizziness, ataxia, drowsiness, stupor, nausea, vomiting, restlessness, agitation, disorientation; tremor, involuntary movements, opisthotonos, abnormal reflexes (slowed or hyperactive); mydriasis, nystagmus; flushing, cyanosis, urinary retention, hypotension, hypertension, coma. The EEG may show dysrhythmias. The laboratory findings have included leukocytosis, reduced leukocyte count, glycosuria and acetonuria.

Treatment: No known specific antidote. Induce emesis. Perform gastric lavage. Watch vital signs and administer symptomatic treatment as required. Hyperirritability may be controlled by the administration of parenteral barbiturates. Barbiturates should not be used if monoamine oxidase inhibitors have also been taken by the patient, either in overdose or in recent therapy (within two weeks). Barbiturates may induce respiratory depression, particularly in children, therefore, have equipment available for artificial ventilation and resuscitation. Paraldehyde may be used to counteract muscular hypertonus without producing respiratory depression. Treat shock (circulatory collapse) with supportive measures, including intravenous fluids, oxygen, and corticosteroids. Electrocardiogram should be monitored, particularly in children, to detect any cardiac arrhythmias or conduction defects.

Dosage and Administration

Use in Epilepsy (see Indications): A low initial daily dosage with a gradual increase in dosage is advised. Dosage should be adjusted to the needs of the individual patient.

Adults and Children over 12 years of age: Initially: 100 to 200 mg once or twice a day. The initial dosage is progressively increased, until the best response is obtained, up to 600 mg daily. Usual Daily Dosage: 600 mg, however up to 800 to 1000 mg have been used for short periods. As soon as disappearance of seizures has been obtained and maintained, dosage should be reduced very gradually until a minimum effective dose is reached.

Children 6-12 Years of Age: Initially, 100 mg in divided doses on the first day. Increase gradually by adding 100 mg per day until the best response is obtained. Dosage should generally not exceed 1000 mg daily. As soon as disappearance of seizures has been obtained and maintained, dosage should be reduced very gradually until a minimum effective dose is reached.

Use in trigeminal neuralgia: Initial daily dosage: 100 mg twice daily may be increased by 200 mg per day until relief of pain is obtained. Usual dosage: 200 to 1000 mg daily. Up to 1200 mg daily may be necessary. As soon as relief of pain has been obtained and maintained, progressive reduction in dosage should be attempted until a minimum effective dosage is reached. Because trigeminal neuralgia is characterized by periods of remission, attempts should be made to reduce or discontinue the use of TEGRETOL at intervals of not more than 3 months, depending upon the individual clinical course.

Prophylactic use in trigeminal neuralgia is not recommended.

Administer in two or three divided doses daily, with meals whenever possible.

Dosage Forms

TEGRETOL® tablets 200 mg: Each white, round, flat, bevelled-edge double-scored tablet engraved GEIGY on one side contains 200 mg carbamazepine.

TEGRETOL® Chewtabs™ 100 mg: Pale pink, round, flat, bevel-edged tablets with distinct red spots. GEIGY engraved on one side and MR on the other. Fully bisected between the M and R. Each chewable tablet contains 100 mg carbamazepine.

TEGRETOL® Chewtabs™ 200 mg: Pale pink, oval biconvex tablets with distinct red spots. GEIGY engraved on one side and PU on the other. Fully bisected between the P and U. Each chewable tablet contains 200 mg carbamazepine.

Availability

TEGRETOL® tablets 200 mg: Bottles of 100 and 500 tablets. Protect from heat and humidity. **TEGRETOL® Chewtabs™ 100 mg:** Bottles of 100. Protect from heat and humidity.

* **TEGRETOL® Chewtabs™ 200 mg:** Bottles of 100. Protect from heat and humidity. (Available September 1985.)

Full information available on request.

Geigy

Mississauga, Ontario
L5N 2W5

G-5088

The Added Value Of

Benefit from the Added Value of Nicolet Systems

“Tough buyers” realize that getting the lowest price does not guarantee the best value. The added value of our unique Nicolet Systems provides you with the security of:

- Expert training for all Nicolet systems
- Customer service response in two hours or less
- Applications support from our staff of Ph.D.s
- Seminar series featuring world-renowned speakers
- Complete financial packages and alternatives
- Our 18 years of experience in problem-solving instrumentation

Nicolet Pathfinder MEGA

- Internal 8, 16 or 32 channel EP/EEG amplifiers
- Flexible test protocols
- 1.28 megabytes of memory for powerful data analysis
- Topographic Mapping for all clinical/research investigations
- O.R./I.C.U. monitoring for a variety of surgical procedures
- Fully programmable system via MECOL and/or FORTRAN 77



Nicolet BEAM®

- Benchmark data base from childhood to geriatric



Introducing the NEW Nicolet Pathfinder MEGA

- Accurate quantification of patient abnormalities
- Complete physician and technologist training
- Data analysis that matches your pace



Nicolet Electroencephalographs

- 18 or 21 channels
- “Short Menu” allows rapid selection of filters and sensitivity
- Programmable measurement sequences allow automated recordings
- Tailor each montage to your unique requirements



Nicolet Expert Sleep/Wake™ Analyzer


- Cost-effectively analyzes up to four patients simultaneously
- Permits direct validation of analyzed results with raw data
- Performs adaptable analysis of patient's data to accommodate individual variability
- Facilitates detailed analysis of less frequent or short duration events (such as micro-arousals)

Unique Nicolet Systems



Nicolet NIM-2™

- Provides the surgeon with an intraoperative tool to locate and identify a nerve directly in the surgical field
- Continuously monitors EMG activity from muscles innervated by the particular nerve
- Acoustically alerts the surgeon when the particular nerve has been activated
- Contains unique technology to minimize the effects of electrocautery interference




Nicolet Viking

- Unique quantitative capabilities
- Expandable to 8 channels of simultaneous EMG/EP
- Comprehensive, high-quality, integrated reports
- Protocols easily customized by individual users



Nicolet Magnetic Stimulator

- Fast—no electrodes or skin preparation required
- Painless—ideal for children
- Easily stimulates deep structures
- Extensive safety features for both operator and patient
- Easily interfaced to other Nicolet instruments



Nicolet CA2000

- Comprehensive Evoked Potential and EMG testing
- User-friendly menu operation with 72 sets of user-defined parameters
- Large color screen with optional remote monitors
- Nicolet-engineered to the highest O.R./I.C.U. standards



Nicolet Compact Four

- All Auditory, Visual and Somatosensory Evoked Potentials
- Complete range of EMG protocols
- Full-feature ENG and ENOG testing
- ERG and EOG for total visual testing



Electrodes and Supplies

In addition to our complete line of quality systems, Nicolet offers a full line of EEG/EMG/EP electrodes and accessories. For our latest Supplies Catalog and specific brochures on any of our unique Nicolet Systems simply call **TOLL FREE**


Ontario: 1-800-268-2058
Eastern/Western Canada: 1-800-387-3385

In Quebec Call: 514-678-2134

Nicolet Instrument Canada Inc.
1-1200 Aerowood Drive
Mississauga, Ontario
L4W 2S7

Nicolet
INSTRUMENTS OF DISCOVERY

Productive Antispastic



Without Therapy.



With Oversedation.

Information for Authors

The Canadian Journal of Neurological Sciences publishes original articles in the clinical and basic neurosciences. Manuscripts are considered for publication with the understanding that, except for identified review articles, they have not been published elsewhere except in abstract form and are not under simultaneous consideration by another publication. Manuscripts should be submitted to:

The Editor
Canadian Journal of Neurological Sciences
Faculty of Medicine,
University of Calgary
3330 Hospital Drive N.W.
Calgary, Alberta T2N 4N1

Manuscripts and all illustrations should be submitted in triplicate. Papers will be accepted in English or French. All papers should be accompanied by an abstract or a résumé of approximately 150 words on a separate page, preferably in both languages, although the Journal will provide the translation if requested. All manuscripts should be double spaced throughout, including references and legends for illustrations. Margins of at least 25 mm should be left on all sides.

For detailed instructions regarding style and layout, authors should refer to "Uniform requirements for manuscripts submitted to biomedical journals". Copies of this document may be obtained by writing to the Journal office, but the main points will be summarized here. Articles should be subdivided under conventional headings of "introduction", "methods and materials", "results" and "discussion" but other headings and subheadings will be considered if more suitable for a particular manuscript. A title page should identify the title of the article, authors, name of institution(s) from which the work originated, and the address and telephone number of the author to whom communications should be addressed. Pages of text should be numbered consecutively. Acknowledgements, including recognition of financial support, should be typed on a separate page at the end of the text.

References are to be numbered in the order of citation in the text. Those cited only in tables or in legends for illustrations are numbered in accordance with a sequence established by the first identification in the text of a particular table or illustration. Titles of journals should be abbreviated according to the style used in Index Medicus. References should be complete including the names of the first three authors followed by "et al"

if there are more than three authors, full title, year of publication, volume number, and inclusive pagination for journal articles. Book or chapter references should also include the place of publication and name of the publisher. Examples of correct forms of references follow:

Journals

Poirier LJ, Filion M, Larochelle L, et al. Physiopathology of experimental parkinsonism in the monkey. *Can J Neurol Sci* 1975; 2: 255-263

Chapter in a book

McGeer PL, McGeer EG. Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. *Basic Neurochemistry*. Boston: Little, Brown & Co, 1981: 233-254

Illustrations should be high quality glossy black-and-white photographic prints, preferably 127 x 173 mm (5 x 7"). Original artwork and radiographs should not be submitted. The additional cost of colour illustration must be borne by the author; quotations are available upon request from the Journal office. All figures should be identified on the back with the author's name and figure number. Letters and arrows applied to the figures to identify particular findings should be professional appliques suitable for publication. Photomicrographs should include a calibration bar with the scale indicated on the figure or in the legend. Legends for illustrations should be typed on a separate page from the illustrations themselves.

Tables should each be on a separate page and be identified with the title or heading. Particular care should be taken in the preparation of tables to ensure that the data are presented in the most clear and precise format. Each column should have a short or abbreviated heading. Place explanatory matter in footnotes, not in the heading. Do not submit tables as photographs.

The SI system (système international d'unités) should be used in reporting all laboratory data, even if originally reported in another system. Temperatures are reported in degrees Celsius. Other measurements should be reported in the metric system. English language text may use either British or American spelling, but should be consistent throughout.

Review articles on selected topics also are published by the Journal. These are usually invited, but unsolicited reviews will be considered. It is suggested that authors intending to submit reviews contact the Editor in advance.

Letters to the Editor are welcome. These should be limited to two double-spaced pages and may include one illustration and a maximum of four references.

Therapy Is a Fine Art.



With Lioresal.

Successful rehabilitation requires both spinal spasticity control and alertness. And that's why Lioresal® stands out. Lioresal can control painful flexor spasms, but unlike diazepam, oversedation is rarely a problem^(1,2,3).

And it effectively stops most flexor spasms overnight, so patients can sleep naturally.

Now there's two strengths:

Lioresal 10mg to initiate therapy and Lioresal D.S. 20mg for maintenance.

Considering that Lioresal has an excellent long-term safety profile, it may be your most effective choice for long-term control of spinal spasticity.

Lioresal^(baclofen)

Lioresal 10mg (initiation therapy)
Lioresal D.S. 20mg (maintenance therapy)

Geigy

Mississauga, Ontario
L5N 2W5

PAAB
OCPP
G-5139

For brief prescribing information see page xxi

Information aux Auteurs

Le Journal Canadien des Sciences Neurologiques publie des articles originaux dans les sciences neurologiques, cliniques et fondamentales. Les manuscrits ne sont considérés pour publication qu'à la condition expresse, à l'exception des articles de revue clairement identifiés comme tel, qu'ils n'aient pas été publiés ailleurs, sauf sous forme de résumé et qu'ils ne soient pas sous considération simultanée par un autre journal. Les manuscrits doivent être soumis à:

L'Éditeur
Journal Canadien des Sciences Neurologiques,
Faculté de Médecine,
Université de Calgary,
3330 Hospital Drive, N.W.,
Calgary, Alberta T2N 4N1

Les manuscrits et toutes les illustrations doivent être soumis en triplicata. Les articles seront acceptés en français ou en anglais. Tous les articles doivent être accompagnés d'un résumé d'environ 150 mots, sur page séparée, préférablement dans les deux langues, quoique le Journal puisse fournir cette traduction sur requête. Les manuscrits doivent être dactylographiés complètement à double interligne y compris les références et les légendes pour illustrations. Des marges d'au moins 25 mm doivent être laissées de tous les côtés.

Pour les conseils plus détaillés sur le style et la présentation du texte, les auteurs doivent se référer au texte intitulé "Règlements uniformes pour les manuscrits soumis aux journaux biomédicaux". On peut obtenir une copie de ce document en écrivant au bureau du Journal, mais en voici les principaux points: Les articles doivent être présentés selon le plan habituel: "Introduction", "Matériel et méthodes", "Résultats" et "Discussion", mais il est possible d'employer d'autres titres ou sous-titres si nécessaire pour un manuscrit en particulier. Sur une page titre séparée on doit identifier le titre de l'article, les auteurs, les institutions d'où origine le travail, ainsi que l'adresse et le numéro de téléphone de l'auteur à qui devront être adressées les communications. Les remerciements, incluant ceux pour l'appui financier, doivent être dactylographiés sur page séparée à la fin du texte. Les références doivent être numérotées dans l'ordre où elles sont citées dans le texte. Celles qui sont citées seulement dans les tableaux ou légendes d'illustrations sont numérotées selon la séquence établie par la première identification dans le texte de ces tableaux ou illustrations particulières. Les titres des Journaux doivent être abrégés selon le style utilisé dans Index Medicus. Les références doivent être complètes, incluant le nom des trois premiers auteurs suivis de "et al", s'il y a plus de trois auteurs, le titre complet, l'année de publication, le

numéro du volume et les premières et dernières pages de l'article. Les références aux livres et chapitres de livres doivent aussi inclure le lieu de la publication et le nom de la maison d'édition. Les exemples corrects suivants peuvent être utilisés:

Journaux

Poirier LJ, Filion M, Larochelle L, et al. Physiopathology of experimental parkinsonism in the monkey. *Can J Neurol Sci* 1975; 2: 255-263

Chapitre de livre

McGeer PL, McGeer EG, Amino acid neurotransmitters. In: Siegel GJ, Albers RW, Agranoff BW, Katzman R, eds. *Basic Neurochemistry*. Boston: Little, Brown & Co, 1981: 233-254

Les **illustrations** doivent être sur papier brillant de haute qualité et imprimés en blanc et noir, préférablement 127 x 173 mm (5 x 7"). Les illustrations et photographies originales ne doivent pas être soumises. Le coût supplémentaire des illustrations en couleur revient entièrement à l'auteur; les coûts détaillés peuvent être obtenus directement au bureau du Journal. Il faut identifier toutes illustrations en inscrivant au dos le nom de l'auteur et le numéro. Toutes lettres ou flèches appliquées aux illustrations pour identifier un aspect particulier doivent être de qualité professionnelle. Les photomicrographies doivent inclure une barre de calibration dont l'échelle est mentionnée dans la légende. Les légendes des illustrations doivent être dactylographiées sur une page séparée de celles-ci.

Les **tableaux** doivent être sur des pages séparées et être identifiés avec titre. On doit prendre un soin particulier dans la préparation de ces tableaux afin d'assurer que les données soient présentées avec le format le plus clair et le plus précis possible. Chaque colonne doit avoir un court titre. Les explications doivent être placées en dessous du tableau et non en sous-titre. Un tableau ne doit pas être soumis sous forme de photographie.

On doit employer le système international d'unités (SI) pour toutes données de laboratoire, même si celles-ci sont originellement présentées dans un autre système. Les températures doivent être citées en degrés Celsius. Les autres données doivent utiliser le système métrique. Les textes en anglais peuvent utiliser l'orthographe anglais ou américain, mais cet usage doit être constant.


Le Journal publie également des **articles de revue** sur des sujets sélectionnées. Ces articles sont généralement sur invitation, mais, à l'occasion, une revue non sollicitée peut être acceptée. Il serait préférable que les auteurs ayant l'intention de soumettre une telle revue contactent d'abord l'Éditeur.

Nous accueillons les **lettres à l'Éditeur**. Celles-ci doivent se limiter à deux pages, double interligne et peuvent contenir une seule illustration et ne citer qu'un maximum de quatre références.

New Dimension in EEG and Evoked


SEEG

- ★ Advanced electroencephalography and evoked potentials testing
- ★ Up to 32 recording channels
- ★ Software—control using a “mouse”
- ★ Storage of raw and digitally processed EEG on (hard)disk or streaming tape
- ★ Review of EEG in any desired montage
- ★ Software for spectral, spatial and statistical analysis and for specific applications
- ★ Topographic display (“brain—mapping”) of all EEG and EP data




NeuroScope


- ★ Unique touch screen control
- ★ Performs up to four—channel auditory, visual and somatosensory evoked potentials
- ★ Can be configured for EEG, CSA and EP Monitoring
- ★ Computer—generated electrode montage including impedance check
- ★ All stimulator functions for VEP, AEP and SEP
- ★ Test results on floppy disk for review and analysis
- ★ Built in thermal printer




Electroencephalography



EEG and EP Monitoring During Carotid Endarterectomy




Quantitative Analysis



Evoked Potentials in Brain and Spinal Surgery



DANTEC ELECTRONICS Ltd
140 Shorting Road
Scarborough
Ontario M1S 3S6
Canada
Telephone: (416) 298-2091
Telex: 6525137 dantec tor



SEEG

NeuroScope

ANOTHER UNEVENTFUL DAY.

DILANTIN

Extended Phenytoin Sodium Capsules, U.S.P.
100 mg
ANTICONSULSANT

INDICATIONS

Dilantin is indicated for the control of generalized tonic-clonic (grand mal) seizures and complex partial (psychomotor) seizures.

CONTRAINDICATIONS

Dilantin is contraindicated in those patients with a history of hypersensitivity to hydantoin products.

WARNINGS

Abrupt withdrawal of phenytoin in epileptic patients may precipitate status epilepticus.

Phenytoin is not indicated in seizures due to hypoglycemia or other causes which may be immediately identified and corrected.

Phenytoin metabolism may be significantly altered by the concomitant use of other drugs such as:

A. Barbiturates may enhance the rate of metabolism of phenytoin. This effect, however, is variable and unpredictable. It has been reported that in some patients the concomitant administration of carbamazepine resulted in an increased rate of phenytoin metabolism.

B. Coumarin anticoagulants, disulfiram, phenylbutazone, and sulfaphenazole may inhibit the metabolism of phenytoin, resulting in increased serum levels of the drug. This may lead to an increased incidence of nystagmus, ataxia, or other toxic signs.

C. Isoniazid inhibits the metabolism of phenytoin so that with combined therapy, patients who are slow acetylators may suffer from phenytoin intoxication.

D. Tricyclic antidepressants in high doses may precipitate seizures, and the dosage of phenytoin may have to be adjusted accordingly.


Usage in Pregnancy: The effects of Dilantin in human pregnancy and nursing infants are unknown.

The prescribing physician will have to determine the risk/benefit in treating or counselling epileptic women of childbearing potential.

PRECAUTIONS

The liver is the chief site of biotransformation of phenytoin, patients with impaired liver function may show early signs of toxicity. Elderly patients or those who are gravely ill may show early signs of toxicity.

A small percentage of individuals who have



See Alternative Dose

been treated with phenytoin have been shown to metabolize the drug slowly. Slow metabolism may be due to limited enzyme availability and lack of induction; it appears to be genetically determined.

Phenytoin has been associated with reversible lymph node hyperplasia. If lymph node enlargement occurs in patients on phenytoin, every effort should be made to substitute another anticonvulsant drug or drug combination.

Drugs that control generalized tonic-clonic (grand mal) seizures are not effective for absence (petit mal) seizures. Therefore, if both conditions are present, combined drug therapy is needed.

Hyperglycemia, resulting from the drug's inhibitory effect on insulin release, has been reported. Phenytoin may also raise the blood sugar level in persons already suffering from hyperglycemia.

ADVERSE REACTIONS

Central Nervous System: The most common manifestations encountered with phenytoin therapy include nystagmus, ataxia, slurred speech, and mental confusion. Dizziness, insomnia, transient nervousness, motor twitchings, and headache have also been observed. These side effects may disappear with continuing therapy at a reduced dosage level.

Gastrointestinal System: Phenytoin may cause nausea, vomiting, and constipation. Administration of the drug with or immediately after meals may help prevent gastrointestinal discomfort.

Integumentary System: Dermatological manifestations sometimes accompanied by fever have included scarlatiniform or morbiliform rashes.

Hemopoietic System: Hemopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia.

Other: Gingival hyperplasia occurs frequently; this incidence may be reduced by good oral hygiene including gum massage, frequent brushing and appropriate dental care. Polyarthropathy and hirsutism occur occasionally. Hyperglycemia has been reported. Toxic hepatitis, liver damage, and periarteritis nodosa may occur and can be fatal.

MANAGEMENT OF OVERDOSE

The mean lethal dose in adults is estimated to be 2 to 5 grams. The cardinal initial symptoms are nystagmus, ataxia and dysarthria. The patient then becomes comatose, the pupils are unresponsive and hypotension occurs. Death is due to respiratory depression and apnea. Treatment is nonspecific since there is no known antidote. First, the stomach should be emptied. If the gag reflex is absent, the airway should be supported. Oxygen, vasopressors and assisted ventilation may be necessary for central nervous system, respiratory and cardiovascular depression. Finally, hemodialysis can be considered since phenytoin is not completely bound to plasma proteins.

DOSAGE AND ADMINISTRATION

Dosage should be individualized to provide maximum benefit. In some cases, serum blood level determinations may be necessary for optimal dosage adjustments — the clinically effective serum level is usually 10-20 mcg/mL.

Adult Dose: Patients who have received no previous treatment may be started on one 100 mg Dilantin Capsule three times daily and the dose then adjusted to suit individual requirements.

Pediatric Dose: Initially, 5 mg/kg/day in two or three equally divided doses, with subsequent dosage individualized to a maximum of 300 mg daily. A recommended daily maintenance dosage is usually 4 to 8 mg/kg. Children over 6 years old may require the minimum adult dose (300 mg/day). Pediatric dosage forms available include a 30 mg Capsule, a 50 mg palatably flavoured Infatab, or an oral suspension form containing 30 or 125 mg of Dilantin in each 5 mL.

Alternative Dose: Once-a-day dosage for adults with 300 mg of Dilantin may be considered if seizure control is established with divided doses of three 100 mg Capsules daily.

HOW SUPPLIED

Dilantin 100 mg Capsules; in bottles of 100 & 1000.

Complete prescribing information available upon request.

Dilantin. Start with it. Stay with it.

PARKE-DAVIS

Parke-Davis Canada Inc., Scarborough, Ontario



*Reg. T.M. Parke, Davis & Company, Parke-Davis Canada Inc., auth. user.



See IBC

Counterpoint

100... ,plait\ v i to intrigue against, or
2counte:point n : a plot opposed to another
coun-ter-point \'kaunt-er-póint\ n 1 a : one
or more independent melodies added above or
below a given melody 2 a : a complementing
or contrasting item : OPPOSITE b : use of contrast
or interplay of elements in a work of art
1coun-ter-poise \-póiz\ v [ME *countrepe*
to... to weigh... more at

The next generation of EMG technology, today.

Counterpoint represents the start of a new era in electromyograph technology.

A system so powerful and flexible it challenges the very definition of what EMG technology can accomplish.

Imagine. One instrument that virtually does it all. And does it fast and accurately. Thanks in large part to the quality of our electrodes and amplifiers. And because at the heart of the system we've incorporated the most advanced signal processor in the industry.

Combine that power with an impressive range of software applications, and you've got a system ready to handle the most demanding jobs, from spontaneous activity and motor nerve conduction velocity to single fiber EMG and power spectrum analysis. Plus more.

And because we know how important it is for you to concentrate on your patient - we've done everything in our power to make Counterpoint as easy to use as possible. The software is user-friendly, footswitch allows you to conduct investigations - hands free - and the electrode arm can be connected to either side of the control panel for comfortable use for everyone.

But the most surprising news is that Counterpoint is totally open to your needs. Data storage and filing can take place in an IBM Personal System/2 or AT compatible environment, so you'll never be left behind by the advent of new technologies or software developments.

Counterpoint masterfully orchestrates all the possibilities in one system. It promises to satisfy the most demanding EMG specialists in the field, and at the same time, makes your job a whole lot easier. And after all, isn't that the point?

Counterpoint from Dantec. Advanced technology in harmony with man.

Please call or write for more information.



DANTEC

Electromedical and
Scientific Equipment Ltd.
140 Shorting Road
Scarborough, Ontario, M1S 3S6
(416) 298-2091




There's a new trend in treating Parkinson's disease.


Enhance the ability to cope with daily living

Dose-related fluctuations in therapeutic efficacy, abnormal movements, on-off phenomena – all such problems which tend to arise during prolonged therapy have been shown to be less severe when the total daily dosage of levodopa is divided into more frequent, smaller doses of 'Prolopa' 50/12.5.¹

Levodopa plasma levels – high dose, low frequency²



Levodopa plasma levels – low dose ('Prolopa' 50/12.5), high frequency²



Changes in plasma levels demonstrate that more frequent, smaller doses of 'Prolopa' may help smooth daily performance for Parkinson patients.

Prescribe 'Prolopa' in low doses from the start of levodopa treatment

A low dose of 'Prolopa' (50/12.5) b.i.d. or t.i.d. initiated and maintained lasting therapeutic benefits for the majority of patients in a two-year study of the elderly with Parkinson's disease. Nausea and vomiting were not significant problems with this regimen.³

Improve compliance

With 'Prolopa' there is no tablet to break when using lower dosages. A 'Prolopa' 50/12.5 capsule provides the entire prescribed low dose. More convenient, easier for a Parkinsonian patient.

And 'Roche' has developed a Parkinson Care Program to assist physicians in the management of patients, available free from Hoffmann-La Roche.

Prolopa[®]

(levodopa/benserazide) 4:1

Efficacious, and very cost effective⁴



Original Research in Medicine and Chemistry

(xvi)

For brief prescribing information see page xiii

PAAB
CCPP